Table 1.
First author, year | Study type | No. of patients |
Mean onabotA dose/injection |
Duration of effect |
Definition of duration | Country of origin |
---|---|---|---|---|---|---|
Mean (±SD) units | Mean (±SD) | |||||
Benecke 2005 [17] |
Prospective, randomized, double-blind, parallel-group, noninferiority study |
232 |
138.9 ± 46.8 |
94.3 ± 31.4 days |
Interval between injection and first visit at which TWSTRS severity score reached 80% of baseline |
Ex-US |
Bihari 2005 [6] |
Prospective, single-arm, crossover study |
12a |
131 |
64.3 days |
Time to reach 70% TWSTRS score |
Ex-US |
Brashear 2005 [3] |
Retrospective |
172b |
241.80-254.07 |
108.48 days (year 1) |
Interval between treatments |
US |
Brashear 2000 [25] |
Retrospective |
60 |
263 |
15.5 ± 3.4 weeks |
Interval between visits |
US |
Brashear 1998 [27] |
Prospective, single-center study |
149c |
219.8 ± 63.5 |
142.9 ± 85.8 days |
Average time between treatments |
US |
Brin 2008 [29] |
Prospective, open-label, multicenter study |
326 |
187.0 ± 76.5 |
110.2 ± 91.8 days |
Time from treatment injection to date of next injection |
US/Ex-US |
Brockmann 2012 [24] |
Retrospective |
20 |
175 ± 76 |
10.7 ± 1.9 weeks |
Time between last treatment and first subjective notice of reduction of benefit from the treatment |
Ex-US |
Camargo 2008 [18] |
Prospective, single-center study |
85 |
151.05 ± 52.55 |
89.1 ± 21.8 days |
Patient-reported time to return of symptoms |
Ex-US |
Dubinsky 1991 [28] |
Prospective cohort |
84 |
269 ± 39 |
107 ± 49 days |
Time from initial injection until patient-reported worsening of symptoms |
US |
Jankovic 2003 [19] |
Prospective, single-center study |
119 |
223.9 ± 73.0 |
14.6 ± 5.6 weeks |
Not specified |
US |
Jankovic 1990 [26] |
Prospective cohort |
205 |
105.4 ± 33.8 |
14.0 ± 6.9 weeks |
Duration of peak effect |
US |
Maia 2010 [20] |
Retrospective |
67 |
204.79 |
13.01 weeks |
Duration which patient had any benefit from treatment |
Ex-US |
Meija 2005 [21] |
Retrospective |
16d |
221.2 ± 129.4 |
15.4 ± 3.4 weeks |
Not specified |
US |
Mohammadi 2009 [7] |
Prospective cohort |
44 |
145 ± 44 |
10 ± 2.4 weeks |
Not specified |
Ex-US |
Naumann 2002 [8] |
Prospective, randomized, double-blind, crossover study |
59 |
155 ± 51 |
13.9 ± 2.6 weeks |
Time to TWSTRS severity score ≥10 and rotational score ≥1 |
Ex-US |
68 |
157 ± 44 |
13.6 ± 2.4 weeks |
||||
Odergren 1998 [22] |
Prospective, randomized, double-blind, parallel-group study |
35 |
152 ± 45 |
80.7 ± 14.4 days |
Time to retreatment |
Ex-US |
Quagliato 2010 [30] |
Prospective, randomized, double-blind study |
12e |
NR |
11.7 ± 3.4 weeks |
Interval between day of treatment and patient-reported waning effect |
Ex-US |
Ranoux 2002 [23] | Prospective, randomized, double-blind, crossover study | 51 | 104.4 ± 20.6 | 89.1 ± 19 days | Interval between day of treatment and patient-reported waning of effect | Ex-US |
a48 total patients; only 12 had CD. bCase report forms. c156 total patients; 149 had idiopathic CD. d45 total patients; 16 had CD. e24 total patients; 12 received onabotulinumtoxinA.
Abbreviations: NR not reported, onabotA onabotulinumtoxinA, TWSTRS Toronto Western Spasmodic Torticollis Rating Scale.